Gilead Sciences, Inc.

K.u. Leuven Research & Development

Other

Genentech, Inc.

Theravance, Inc.

University of Texas System

Gerhard Puerstinger

Puerstinger, Gerhard

David A Oare

Choung U Kim

Steven S Bondy

Richard L Mackman

James Ming Chen

Mathai Mammen

William John Watkins

Hyung-Jung Pyun

Aesop Cho

Jennifer R Zhang

Thorsten A Kirschberg

Adrian S Ray

Lee Shun Chong

Sundaramoorthi Swaminathan

Maria Fardis

Carina E Cannizzaro

Constantine G Boojamra

Xiaowu Chen

Alan X Huang

Christopher P Lee

David Y Markevitch

Vidya K Prasad

Ralph F Hirschmann

Robert S McDowell

William A Lee

Haolun Jin

Winston C Tse

Kuei-Ying Lin

Vahid Zia

Mark E Reynolds

James C Marsters

Rosemarie Sherlock

Peter H Nelson

John P Burnier

Brian C Cunningham

Johan Neyts

Lijun Zhang

David G Lowe

Adam D Hughes

Craig Husfeld

Thomas Gadek

Daniel Marquess

Yu-Hua Ji

John H Griffin

Li Li

James Bradley Aggen

Edmund J Moran

Joseph L Goldstein

Michael S Brown

Reza Oliyai

Eric Dowdy

Sarah Dunham

Mark S Stanley

Daniel J Burdick

Richard D Wilson

Thomas E Rawson

Ioanna Stergiades

Todd C Somers

Terrence C Dahl

Trevor Mischki

Steven H Krawczyk

Craig W Crowley

Gerhard Pürstinger

Craig S Gibbs

Guy L James

Rosemarie O'Shea

Manoj C Desai

Oliver L Saunders

Weijiang Zhang

Junning Lee

Jason K Perry

Sundaramoorthi Swaninathan

Will Watkins

Eric Davis Dowdy

Pyrrolo[2,3-c]pyridine or pyrrolo[3,2-c]pyridine compounds having the general formula (A), wherein the dashed lines, X, Y and Rthrough Rare as defined in the specification. The compounds are useful in the prophylaxis or treatment of viral infections.

Viral inhibitors

The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Antiviral phosphonate analogs

A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided. 

Pyridazine compound and use thereof

The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections.

Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment

This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.

Substituted 4-amino-benzylpiperidine compounds

This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.

Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds

A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating compound (1) are provided.

A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Phosphonate inhibitors of HCV

The compound 5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2 -(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine, together with the salts and solvates thereof. Also provided are compositions comprising this compound and pharmaceutically acceptable carriers, as well as the use of such compositions in the treatment or prophylaxis of viral infections.

Imiadazo[4,5-c] pyridine compound and method of antiviral treatment

The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one compound having the general formula (A): wherein U is N or C; X is selected from C-Calkylene, Calkenylene or Calkynylene, where each may include one or more intrachain heteroatoms selected from O, S, or NR, provided any such heteroatom is not adjacent to the N in the ring; Ris selected from aryl, aryloxy, arylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl-N(R)&#x2014;, or heterocycle, where each said substituent is optionally substituted with at least one R, provided that for cycloalkenyl the double bond is not adjacent to a nitrogen; and the other substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula, their pharmaceutically acceptable formulations and their use as a medicine or to treat or prevent viral infections.

Imidazo[4,5-d]pyrimidines, their uses and methods of preparation

Growing community of inventors

Belmont, CA, United States of America

David A Oare